Afatinib use in non-small cell lung cancer previously sensitive to epidermal growth factor receptor inhibitors: The United Kingdom Named Patient Programme

作者：Khan F; Ottensmeier C; Popat S; Dua D; Dorey N; Ellis S; Szabo M; Upadhyay S; Califano R; Chan S; Lee L; Ali C W; Nicolson M; Bates A T; Button M; Chaudhuri A; Mulvenna P; Shaw H M; Danson S J^*

来源：European Journal of Cancer, 2014, 50(10): 1717-1721.

DOI：10.1016/j.ejca.2014.03.001

• Afatinib
• Non-small cell lung cancer
• EGFR

Introduction: Afatinib prolongs progression-free survival (PFS) in patients with non-small cell lung cancer (NSCLC) who were previously sensitive to erlotinib or gefitinib. This study investigated experience of afatinib under a Named Patient Use (NPU) programme.
Patients and methods: Retrospective data for 63 patients were collected, including demographics, dose, toxicity and clinical efficacy.
Results: Response rate and median PFS were 14.3% and 2.6 months, respectively. Diarrhoea and rash were the most common toxicities; 46% of patients required a dose reduction and 41% had a dose delay.
Conclusions: Efficacy and safety in the NPU programme are consistent with the LUX-Lung 1 trial.

• 出版日期2014-7